10:41 AM EDT, 04/29/2025 (MT Newswires) -- Astrazeneca ( AZN ) said Tuesday its Calquence fixed-duration regimen was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with previously untreated chronic lymphocytic leukaemia.

CHMP's positive opinion was based on a phase 3 trial that indicated that Calquence combinations with venetoclax and obinutuzumab showed improved progression-free survival compared with chemoimmunotherapy, according to a statement.

Shares were up 0.6% in recent trading.

Price: 70.38, Change: +0.45, Percent Change: +0.64